Company logo

GLSI - Greenwich LifeSciences, Inc.

NASDAQ -> Healthcare -> Biotechnology
Stafford, United States
Type: Equity

GLSI price evolution
GLSI
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Current assets
Cash $9.14 $10.94 $11.91 $13.47
Short term investments
Net receivables
Inventory
Total current assets $9.14 $10.94 $11.91 $13.48
Long term investments
Property, plant & equipment
Goodwill & intangible assets $0.01 $0.01 $0.01 $0.01
Total noncurrent assets $0.01 $0.01 $0.01
Total investments
Total assets $9.15 $10.95 $11.92 $13.48
Current liabilities
Accounts payable $0.23 $0.3 $0.22 $0.22
Deferred revenue
Short long term debt
Total current liabilities $0.3 $0.3 $0.24 $0.26
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $0.3 $0.3 $0.24 $0.26
Shareholders' equity
Retained earnings -$47.62 -$45.23 -$43.6 -$41.47
Other shareholder equity
Total shareholder equity $8.85 $10.65 $11.68 $13.21
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $13.47 $27.2 $28.66 $0.01
Short term investments
Net receivables
Inventory
Total current assets $13.48 $27.22 $28.66 $0.01
Long term investments
Property, plant & equipment
Goodwill & intangible assets $0.01 $0.01 $0.02 $0.02
Total noncurrent assets $0.02 $0.02
Total investments
Total assets $13.48 $27.22 $28.68 $0.03
Current liabilities
Accounts payable $0.22 $0.22 $0.71 $0.73
Deferred revenue
Short long term debt $0.28 $0.64
Total current liabilities $0.26 $0.39 $1.05 $1.38
Long term debt
Total noncurrent liabilities
Total debt $0.28 $0.64
Total liabilities $0.26 $0.39 $1.05 $1.38
Shareholders' equity
Retained earnings -$41.47 -$33.65 -$29.08 -$27.21
Other shareholder equity
Total shareholder equity $13.21 $26.83 $27.63 -$1.35
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $2.16 $1.38 $1.83 $2.46
Selling, general & administrative $0.34 $0.37 $0.41 $0.44
Total operating expenses $2.5 $1.75 $2.24 $2.89
Operating income -$2.5 -$1.75 -$2.24 -$2.89
Income from continuing operations
EBIT -$2.39 -$1.63 -$2.12 -$2.79
Income tax expense
Interest expense
Net income
Net income -$2.39 -$1.63 -$2.12 -$2.79
Income (for common shares) -$2.39 -$1.63 -$2.12 -$2.79
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $6.48 $3.56 $1.06 $2.61
Selling, general & administrative $1.56 $1.04 $0.81 $0.82
Total operating expenses $8.04 $4.6 $1.86 $3.43
Operating income -$8.04 -$4.6 -$1.86 -$3.43
Income from continuing operations
EBIT -$7.83 -$4.57 -$1.86 -$3.43
Income tax expense
Interest expense
Net income
Net income -$7.83 -$4.57 -$1.86 -$3.43
Income (for common shares) -$7.83 -$4.57 -$1.86 -$3.43
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$2.39 -$1.63 -$2.12 -$2.79
Operating activities
Depreciation $0 $0 $0 $0
Business acquisitions & disposals
Stock-based compensation $0.59 $0.59 $0.59 $0.59
Total cash flows from operations -$1.8 -$0.97 -$1.56 -$2.17
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing
Effect of exchange rate
Change in cash and equivalents -$1.8 -$0.97 -$1.56 -$2.17
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$7.83 -$4.57 -$1.86 -$3.43
Operating activities
Depreciation $0 $0 $0 $0
Business acquisitions & disposals
Stock-based compensation $1.74 $0.66 $0.68 $0.19
Total cash flows from operations -$6.2 -$4.29 -$1.15 -$0.29
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock -$7.54 $3.11 $30.17
Net borrowings -$0.28 -$0.36 $0.21
Total cash flows from financing -$7.54 $2.84 $29.81 $0.21
Effect of exchange rate
Change in cash and equivalents -$13.74 -$1.46 $28.65 -$0.08
Fundamentals
Market cap $256.96M
Enterprise value $247.82M
Shares outstanding 12.85M
Revenue $0.00
EBITDA -$8.93M
EBIT -$8.94M
Net Income -$8.94M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -28.76
EV/Sales N/A
EV/EBITDA -27.75
EV/EBIT -27.73
P/S ratio N/A
P/B ratio 29.03
Book/Share 0.69
Cash/Share 0.71
EPS -$0.70
ROA -78.56%
ROE -80.50%
Debt/Equity 0.02
Net debt/EBITDA 0.99
Current ratio 30.76
Quick ratio 30.76